uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA’s Breakthrough ...
The last time I wrote an article on uniQure (QURE) it was with respect to a Seeking Alpha article entitled "uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts". With respect ...
uniQure N.V. has announced progress regarding its investigational gene therapy AMT-130 for Huntington's disease, aligning with the FDA on key components necessary for a Biologics License Application ...
uniQure announces FDA's Breakthrough Therapy designation for AMT-130, with promising Phase I/II trial safety data and upcoming regulatory updates. uniQure N.V. has announced that its gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results